|

Coronavirus: Scientists hail 'groundbreaking' discovery of antibody which prevents infection – SKY

As scientists from around the world rush to find a cure for the coronavirus, picking up on an article by SKY News, there is news of research into antibodies which target the SARS coronavirus and scientists have identified one that blocks COVID-19.

"Scientists have discovered an antibody which prevents the coronavirus from infecting human cells in "groundbreaking research" which could lead to the development of new treatments," the article reads.

Lead paragraphs

Building on research into the SARS coronavirus, scientists from Utrecht University in the Netherlands, as well as the Erasmus Medical Centre and the company Harbour BioMed (HBM), have identified a potential method of neutralising COVID-19.

They discovered that an antibody which prevents the SARS virus from infecting human cells could also block the novel coronavirus from infecting human cells too, according a peer reviewed study published on Monday in the journal Nature Communications.

Testing their collection of antibodies on cultured human cells, researchers discovered one which binds to a specific part which is present in both SARS and the virus causing COVID-19.

Key notes

  • The discovery could offer an initial step towards developing a fully-human antibody to treat or prevent the disease.
  • The neutralising antibody "has potential to alter the course of infection in the infected host, support virus clearance or protect an uninfected individual that is exposed to the virus," said Dr Berend-Jan Bosch, co-lead author on the study.
  • The discovery provided "a strong foundation for additional research to characterise this antibody and begin development as a potential COVID-19 treatment," –  said Dr Berend-Jan Bosch. "The antibody used in this work is 'fully human', allowing development to proceed more rapidly and reducing the potential for immune-related side effects," he added.
  • The fully-human antibody is different from conventional therapeutic antibodies, which are often first developed in other species before being "humanised" so they can be transmitted to people.
  • It was developed using Harbour BioMed's H2L2 transgenic mouse technology - effectively a mouse which has been genetically engineered to contain human genes, enabling researchers to develop "human" antibodies without testing them on living people.
  • "This is groundbreaking research," said Dr Jingsong Wang, the chief executive of HBM.

Market implications

This is undoubtedly good news and should help to put a foundation under markets. However, with trade wars back on the agenda, there is no escaping the prospects of a prolonged season of risk-off, volatility and uncertainty until, a) a cure is implemented, b) a vaccine is developed, c) China is proven innocent of the speculated accusations of the US following an investigation and d) global trade and the world economy can start to heal. 

Author

Ross J Burland

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

More from Ross J Burland
Share:

Editor's Picks

EUR/USD deflates to fresh lows, targets 1.1600

The selling pressure on EUR/USD now gathers extra pace, prompting the pair to hit fresh multi-week lows in the 1.1625-1.1620 band on Friday. The continuation of the downward bias comes in response to further gains in the US Dollar as market participants continue to assess the mixed release of US Nonfarm Payrolls in December.

GBP/USD breaks below 1.3400, challenges the 200-day SMA

GBP/USD remains under heavy fire and retreats for the fourth consecutive day on Friday. Indeed, Cable suffers the strong performance of the Greenback, intensified post-mixed NFP, and trades at shouting distance from its critical 200-day SMA near 1.3380.

Gold flirts with yearly tops around $4,500

Gold keeps its positive bias on Friday, adding to Thursday’s advance and challenging yearly highs in the $4,500 region per troy ounce. The risk-off sentiment favours the yellow metal despite the firmer tone in the Greenback and rising US Treasury yields.

Crypto Today: Bitcoin, Ethereum, XRP risk further decline as market fear persists amid slowing demand

Bitcoin holds $90,000 but stays below the 50-day EMA as institutional demand wanes. Ethereum steadies above $3,000 but remains structurally weak due to ETF outflows. XRP ETFs resume inflows, but the price struggles to gain ground above key support.

Week ahead – US CPI might challenge the geopolitics-boosted Dollar

Geopolitics may try to steal the limelight from US data. A possible US Supreme Court ruling on tariffs could dictate market movements. A crammed data calendar next week, US CPI comes on Tuesday; Fedspeak to intensify.

XRP trades under pressure amid weak retail demand

XRP presses down on the 50-day EMA support as risk-averse sentiment spreads despite a positive start to 2026. XRP faces declining retail demand, as reflected in futures Open Interest, which has fallen to $4.15 billion.